Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families

BackgroundBRCA1 and BRCA2 are the two most important genes associated with familial breast and ovarian cancer susceptibility. In addition, PALB2 has recently been identified as a breast cancer susceptibility gene in several populations. Here we have evaluated whether large genomic rearrangement in these genes could explain some of Finnish breast and/or ovarian cancer families.MethodsAltogether 61 index patients of Northern Finnish breast and/or ovarian cancer families were analyzed by Multiplex ligation-dependent probe amplification (MLPA) method in order to identify exon deletions and duplications in BRCA1, BRCA2 and PALB2. The families have been comprehensively screened for germline mutation in these genes by conventional methods of mutation analysis and were found negative.ResultsWe identified one large deletion in BRCA1, deleting the most part of the gene (exon 1A-13) in one family with family history of ovarian cancer. No large genomic rearrangements were identified in either BRCA2 or PALB2.ConclusionIn Finland, women eligible for BRCA1 or BRCA2 mutation screening, when found negative, could benefit from screening for large genomic rearrangements at least in BRCA1. On the contrary, the genomic rearrangements in PALB2 seem not to contribute to the hereditary breast cancer susceptibility.

[1]  M. Skolnick,et al.  Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family. , 1997, Human molecular genetics.

[2]  D. Stoppa-Lyonnet,et al.  Distinct BRCA1 rearrangements involving the BRCA1 pseudogene suggest the existence of a recombination hot spot. , 2002, American journal of human genetics.

[3]  Chun-Fang Xu,et al.  Complex Regulation of the BRCA1 Gene* , 1997, The Journal of Biological Chemistry.

[4]  L. Chieco‐Bianchi,et al.  Large genomic deletions inactivate the BRCA2 gene in breast cancer families , 2005, Journal of Medical Genetics.

[5]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[6]  Katri Pylkäs,et al.  A recurrent mutation in PALB2 in Finnish cancer families , 2007, Nature.

[7]  A. Kallioniemi,et al.  Search for large genomic alterations of the BRCA1 gene in a Finnish population. , 2005, Cancer genetics and cytogenetics.

[8]  J. Kere,et al.  Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. , 2006, Carcinogenesis.

[9]  G. Taylor,et al.  MLPA and MAPH: New techniques for detection of gene deletions , 2004, Human mutation.

[10]  A. Kallioniemi,et al.  Large genomic BRCA2 rearrangements and male breast cancer. , 2006, Cancer detection and prevention.

[11]  O. Kallioniemi,et al.  Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. , 1997, Human molecular genetics.

[12]  H. Nevanlinna,et al.  Exclusion of large deletions and other rearrangements in BRCA1 and BRCA2 in Finnish breast and ovarian cancer families. , 2001, Cancer genetics and cytogenetics.

[13]  R. Winqvist,et al.  Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. , 1998, American journal of human genetics.

[14]  F. Couch,et al.  Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. , 2006, Molecular cell.

[15]  L. Chieco‐Bianchi,et al.  Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. , 2003, Human molecular genetics.

[16]  I. Bièche,et al.  Characterisation of a 161 kb deletion extending from the NBR1 to the BRCA1 genes in a French breast‐ovarian cancer family , 2003, Human mutation.

[17]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[18]  Petra M. Nederlof,et al.  Analysis of PALB2/FANCN-associated breast cancer families , 2007, Proceedings of the National Academy of Sciences.

[19]  P. Chappuis,et al.  The contribution of germline rearrangements to the spectrum of BRCA2 mutations , 2006, Journal of Medical Genetics.

[20]  A. Mannermaa,et al.  Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families , 2007, Clinical genetics.

[21]  M. Urioste,et al.  Analysis of FANCB and FANCN/PALB2 Fanconi Anemia genes in BRCA1/2-negative Spanish breast cancer families , 2009, Breast Cancer Research and Treatment.

[22]  J. Kirk,et al.  Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families , 2005, Journal of Medical Genetics.

[23]  Arto Mannermaa,et al.  RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. , 2005, Carcinogenesis.

[24]  S. Mazoyer.  Genomic rearrangements in the BRCA1 and BRCA2 genes , 2005, Human mutation.

[25]  H. Nevanlinna,et al.  A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families , 2001, British Journal of Cancer.

[26]  W. Foulkes,et al.  Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women , 2007, Breast Cancer Research.

[27]  Jaana M. Hartikainen,et al.  Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland , 2000, European Journal of Human Genetics.